 Home > Active Pharmaceutical Ingredients > Inhibitor Drugs > Retatrutide for Sale > Retatrutide 2381089-83-2 API

Retatrutide 2381089-83-2 API buy - large image1

Retatrutide 2381089-83-2 API buy - image1

Retatrutide 2381089-83-2 API buy - image2

Retatrutide 2381089-83-2 API buy - image3

Retatrutide 2381089-83-2 API buy - image4

Retatrutide 2381089-83-2 API

5664 Inquiries

Unit Price: Get Latest Price 

CAS No.:

2381089-83-2

Grade:

Industrial Grade

Content:

99%

Port:

shanghai

Brand:

orient

Packaging:

1KG, 5KG, 25KG

Price valid (until):

2026-06-08

Contact Supplier

 Chat Now

Qingdao Orient Chemical Co.,LTD

Company Type:

Trader

Location:

China

Qualification:

Main Products:

pharmaceutical intermediates,peptides,electronic chemicals

 Visit Store

Product Description
Seller Information
Inquiry History

Description

Retatrutide Basic information

Product Name:	Retatrutide
Synonyms:	LY3437943;Retatrutide;GIPR/GLP-1R;Retatrutide/LY3437943/GIPR/GLP-1R;Retaglutide;Retatrutide acetate;LY3437943Retatrutide;Retalutide
CAS:	2381089-83-2
MF:
MW:	0
EINECS:	200-001-8
Product Categories:
Mol File:	Mol File

Retatrutide Chemical Properties

storage temp.	-20°C
solubility	Acetonitrile: Slightly soluble DMSO: Sparingly Soluble: 1-10mg/mLPBS (pH 7.2): Sparingly Soluble: 1-10mg/mL Water: Slightly soluble
form	powder
color	White lyophilized
Water Solubility	Soluble in water (5mg/ml).

Safety Information

MSDS Information

Retatrutide Usage And Synthesis

Description	Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent otropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research. Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent secretion through activity at the GIP receptor (GIPR) or the GLP-1R. Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating and suppressing glucagon secretion in a glucose-dependent manner. Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.
History	Retatrutide (LY-3437943) was discovered by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors) for obesity. The 2024 Lasker~DeBakey Clinical Medical Research Award has been given to Joel Habener and Svetlana Mojsov for their discovery of a new hormone GLP-1(7-37) and to Lotte Knudsen for her role in developing sustained acting versions of this hormone as a treatment for obesity.
Biological Activity	Retatrutide (LY3437943), a single peptide conjugated to a lipid diacid molecule, exerts a powerful agonist effect on the human glucagon‐receptor (GCGR), GIPR, and GLP‐1R. In comparison with the human glucagon and glucagon‐like peptide 1 (GLP‐1), retatrutide exhibits reduced potency (by a factor of 0.3 and 0.4, respectively) on the GCGR and GLP‐1R while displaying enhanced potency at the human GIPR (by a factor of 8.9) when compared to the glucose‐dependentotropic polypeptide (GIP)[7].
Mechanism of action	When incted into mice suffering from diabetes-induced kidney injury, retatrutide was found to markedly reduce albuminuria levels while also increasing renal filtration rate. This was attributed to its ability to activate GLP-1R/GR-dependent signalling pathways, which then produced anti-inflammatory and antiapoptotic effects that protected the kidneys from further damage. Additionally, it has been shown to directly modulate glomerular permeability, thus leading to improved urinary concentration. Initial results indicate that the peptide can induce marked improvements in albuminuria levels within just four weeks of treatment when compared to other treatments for chronic kidney disease such as ACE inhibitors or angiotensin receptor blockers (ARBs). Moreover, retatrutide has demonstrated a greater effect than either ACE inhibitors or ARBs at reducing systolic blood pressure without inducing significant side effects.
Side effects	The most common side effects of retatrutide are gastrointestinal, including: Nausea, Diarrhea, Vomiting, and Constipation. At higher doses, researchers stated these symptoms were "mostly mild to moderate in severity" and typically treated by lowering the dosage. However, 7% of patients also experienced skin tingling. At 24 weeks of treatment, patients' heart rates on higher doses peaked but declined afterward.
in vitro	In vitro, Retatrutide demonstrates similar efficacy to natural glucagon in evoking glucose production within hepatocytes. Meanwhile, in adipocytes, it surpasses native GIP in inducing lipolysis. Retatrutide is effective in reducing weight in individuals with nonsyndromic obesity. Retatrutide demonstrates dosage‐dependent pharmacokinetics, featuring a favourable half‐life of nearly 6 days, enabling convenient weekly administration. Additionally, GLP‐1 and GCG are known to significantly delay GE in humans, while GIP may have no impact on GE. Delayed GE reduces food consumption and, therefore, leads to weight reduction[7].
References	[1] LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept: T. Coskun, et al.; Cell Metab. 34, 1234 (2022) DOI:10.1016/j.cmet.2022.07.013 [2] The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying: S. Urva, et al.; Diabetes Obes. Metab. 25, 2784 (2023) DOI:10.1111/dom.15167 [3] LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial: S. Urva, et al.; Lancet 400, 1869 (2022) DOI:10.1016/S0140-6736(22)02033-5 [4] Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity S.A. Doggrell; Expert Opin. Investig. Drugs 32, 355 (2023) DOI:10.1080/13543784.2023.2206560 [5] Differentiation of human subcutaneous adipocytes and measurement of lipolytic function induced by GIP or LY3437943: A. Regmi & W. Roell; STAR Protoc. 4, 102304 (2023) DOI:10.1016/j.xpro.2023.102304 [6] Gut hormone co-agonists for the treatment of obesity: from bench to bedside: R. Nogueiras, et al.; Nature Metab. 5, 933 (2023) (Review) DOI:10.1038/s42255-023-00812-z [7] Muhammad Naeem, Umm E Salma Shabbar Banatwala, Laiba Imran. “Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence.” Health Science Reports 7 2 (2024).

Shop Tirzepatide API Material-Detailed Image 2

Shop Tirzepatide API Material-Detailed Image 3

Shop Tirzepatide API Material-Detailed Image 4

Shop Tirzepatide API Material-Detailed Image 5

Shop Tirzepatide API Material-Detailed Image 6

Shop Tirzepatide API Material-Detailed Image 7

Shop Tirzepatide API Material-Detailed Image 8

Shop Tirzepatide API Material-Detailed Image 9

Shop Tirzepatide API Material-Detailed Image 10

Shop Tirzepatide API Material-Detailed Image 11

Q1:Do you provide sample?

A: Yes, we can provide free sample, you only need pay the shipping cost.

Q2: What is the lead time?

A: For stock goods, it usually take about 5-7 days by air, 15-30 days by sea,For customized products, the delivery time needs to be confirmed based on the actual situation.

Q3: How can I buy? What is the payment method?

A: You can contract us through Email or you can browse our website:orientchem.cc, we have bank transfer,

Q4:What if there are quality issues？

A：We attach great importance to after-sales service of our products. If there are any quality issues, please contact us within 30 days of receiving the goods and we will handle returns and exchanges for you.

Basic Info

Product Name:

Retatrutide

Other Name:

LY3437943;Retatrutide;GIPR/GLP-1R;Retatrutide/LY3437943/GIPR/GLP-1R;Retaglutide;Retatrutide acetate;LY3437943Retatrutide;Retalutide

CAS No.:

2381089-83-2

Molecular Weight:

EC Number:

200-001-8

Color/Form:

White lyophilized

Categories:

Inhibitor Drugs

Characteristics

Water Solubility:

Soluble in water (5mg/ml).

Storage Conditions:

-20°C

Critical Temperature & Pressure:

-20°C

See More Retatrutide Properties 

Seller Information

Business Type:
Trader

Main Products:
pharmaceutical intermediates,peptides,electronic chemicals

Location:
Room 102, 1st Floor, East Office Building, No. 45 Pengwan Road, Qianwan Bonded Port Area, Qingdao Zone, China (Shandong) Pilot Free Trade Zone

Payment Terms:
100% TT in advance

Average lead Time:
10

Total Annual Revenue:
$10 million-$25 million

Total Employees:
51-100

Year of Establishment:
2024

A reliable supplier is like insurance.

We are mainly specilized in supply of pharmaceutical intermediates, electronic chemicals，food additives, and other fine chemical products.
Integrity is the foundation, quality is life. We would like to work together with you to build a greener and brighter future.

Website: orientchem.cc
Email: scarlett@orientchem.cc
WhatsApp: +86 17753254221

Inquiry History

5664 Inquiries

Country	Product	Purchase Quantity	Date Posted
United States	Retatrutide 2381089-83-2	3 MT	Mar 28, 2026
United Kingdom	Retatrutide - 2381089-83-2	1 G	Feb 10, 2026
United States	Retatrutide CAS 2381089-83-2 10mg vial	20 MT	Mar 7, 2026
United States	Factory Retatrutide API 99% Purity CAS 2381089-83-2	5 KG	Nov 10, 2025
United Kingdom	Peptide powder Retatrutide 99% pure for Body building cas 2381089-83-2 Weight Loss Peptide with COA	1 MT	Mar 22, 2026
United States	2381089-83-2	100 G	Feb 24, 2026
United States	2381089-83-2	100 MT	Dec 9, 2023
United States	Retatrutide 2381089-83-2	200 MG	May 16, 2026
United Kingdom	2381089-83-2 retatrutide	300 MG	Feb 13, 2026
United States	Retatrutide 2381089-83-2 wholesale	500 MT	Nov 3, 2023
United States	Retatrutide CAS 2381089-83-2 99%	10 PCS	Feb 21, 2026
Poland	CAS 2381089-83-2 (Custom Peptide)	40 MT	Apr 10, 2026
Austria	Peptide Retatruide CAS 2381089-83-2	100 MT	Apr 4, 2026
Austria	Retatrutide CAS 2381089-83-2 10mg vial	20 PCS	Feb 10, 2026
United States	Tirzepatide 99.9% Liquid 2381089-83-2 TeruiOP	1 MT	Sep 6, 2023
United States	Retatrutide/LY3437943/GIPR/GLP-1R 98% Powder 2381089-83-2 Senwayer	1 G	Sep 3, 2023
United States	GLP-1 / GIP Retatrutide cas 2381089-83-2	1 MT	Oct 16, 2024
United States	Retatrutide 99% High Quality CAS 2381089-83-2	1 G	Jan 23, 2026
United States	Injection Peptide Tirzepatide/Retatrutide/ Semaglutide Peptides CAS 2381089-83-2	10	Oct 21, 2023
Palestine	Factory 99% Purity Retatrutide Peptide CAS 2381089-83-2 Door-To-Door Service	10 MG	Mar 16, 2026

Go to Page

Post an enquiry for this product

More Choices Find All Products for Sale 

Product Name	Grade / Content	Price	Supplier Name	Details
RL White Powder AE1 Peptide Purity 99% Best Quality AE5mg .	Pharmaceutical Grade/99	$180-181/UNIT FOB	Guangzhou Henghuang Trading Co., Ltd.	Inquiry
China Factory New Produce Retatrutide High Quality 99% Fast Delivery	Pharmaceutical Grade/99		Dongguan Chenguang Technology Co., Ltd.	Inquiry
Retatrutide CAS 2381089-83-2 99% Hot Sale Pharmaceutical Best Service Pharmaceutical Producer	Pharmaceutical Grade/99.69	$80/G FOB	Jinan Million Pharmaceutical Co., Ltd	Inquiry
Retatrutide injection grade weight management USFDA approved factory	/99		Deepharma Peptides/supplement	Inquiry
Hot Seal Salable High Quality Purity Loss Weight Retatrutide Powder 10mg 20mg	Cosmetics Grade/99.9		Hebei Tengchu trading Co., LTD	Inquiry

Retatrutide 2381089-83-2 API

Product Description

Seller Information

Inquiry History

More Choices Find All Products for Sale 

Related Searches